Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 5/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2138370 | 0.90 | MEN1 (0.43) | SMN1; SMN2POLBKDM4EALDH1A1ACHE | |
| SCHEMBL1329399 | 0.89 | ATM (0.41) | SMN1; SMN2KDM4EACHEMAPT | |
| SCHEMBL1328327 | 0.87 | MEN1 (0.40) | SMN1; SMN2KDM4EALDH1A1GAAMAPT | |
| SCHEMBL1328362 | 0.87 | ALDH1A1 (0.33) | SMN1; SMN2POLBALDH1A1CRHR1GAA | |
| SCHEMBL1328114 | 0.86 | CRHR1 (0.33) | SMN1; SMN2POLBCRHR1TSHRKMT2A | |
| SCHEMBL1329703 | 0.85 | P2RX7 (0.35) | SMN1; SMN2KDM4EALDH1A1ACHEGAA | |
| SCHEMBL1327491 | 0.84 | BCHE (0.38) | CRHR1MAPTBCHE | |
| SCHEMBL1327840 | 0.82 | PDCD1LG2 (0.35) | SMN1; SMN2KDM4EALDH1A1ACHECRHR1 | |
| SCHEMBL1327565 | 0.82 | L3MBTL1 (0.35) | KMT2AMEN1 | |
| SCHEMBL1329151 | 0.81 | POLB (0.46) | SMN1; SMN2POLBKDM4EALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | C3AR1, C5AR1, C5AR2 | SMN1; SMN2 4559/4885POLB 4733/4885KDM4E 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.